238 related articles for article (PubMed ID: 27916409)
21. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
[TBL] [Abstract][Full Text] [Related]
22. Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.
Celma CC; Stewart M; Wernike K; Eschbaumer M; Gonzalez-Molleda L; Breard E; Schulz C; Hoffmann B; Haegeman A; De Clercq K; Zientara S; van Rijn PA; Beer M; Roy P
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795442
[TBL] [Abstract][Full Text] [Related]
23. Vaccines for Prevention of Bluetongue and Epizootic Hemorrhagic Disease in Livestock: A North American Perspective.
McVey DS; MacLachlan NJ
Vector Borne Zoonotic Dis; 2015 Jun; 15(6):385-96. PubMed ID: 26086559
[TBL] [Abstract][Full Text] [Related]
24. Bluetongue vaccines: the past, present and future.
Bhanuprakash V; Indrani BK; Hosamani M; Balamurugan V; Singh RK
Expert Rev Vaccines; 2009 Feb; 8(2):191-204. PubMed ID: 19196199
[TBL] [Abstract][Full Text] [Related]
25. Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(-/-) mice conferring protection against serotypes 1 and 4 of bluetongue virus.
Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Benavente J; Brun A; Martínez-Costas JM; Ortego J
Antiviral Res; 2017 Jun; 142():55-62. PubMed ID: 28322923
[TBL] [Abstract][Full Text] [Related]
26. Recombinant vaccines against bluetongue virus.
Calvo-Pinilla E; Castillo-Olivares J; Jabbar T; Ortego J; de la Poza F; Marín-López A
Virus Res; 2014 Mar; 182():78-86. PubMed ID: 24287057
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
[TBL] [Abstract][Full Text] [Related]
28. Vaccines against bluetongue in Europe.
Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
[TBL] [Abstract][Full Text] [Related]
29. Development of an inactivated combined vaccine for protection of cattle against lumpy skin disease and bluetongue viruses.
Es-Sadeqy Y; Bamouh Z; Ennahli A; Safini N; El Mejdoub S; Omari Tadlaoui K; Gavrilov B; El Harrak M
Vet Microbiol; 2021 May; 256():109046. PubMed ID: 33780805
[TBL] [Abstract][Full Text] [Related]
30. Vaccines for bluetongue.
Murray PK; Eaton BT
Aust Vet J; 1996 Jun; 73(6):207-10. PubMed ID: 8893989
[TBL] [Abstract][Full Text] [Related]
31. Duration of protective immunity after a single vaccination with a live attenuated bivalent bluetongue vaccine.
Zhugunissov K; Yershebulov Z; Barakbayev K; Bulatov Y; Taranov D; Amanova Z; Abduraimov Y
Vet Res Commun; 2015 Dec; 39(4):203-10. PubMed ID: 26280208
[TBL] [Abstract][Full Text] [Related]
32. Determination of the minimum protective dose for bluetongue virus serotype 2 and 8 vaccines in sheep.
Modumo J; Venter EH
J S Afr Vet Assoc; 2012 Aug; 83(1):17. PubMed ID: 23327131
[TBL] [Abstract][Full Text] [Related]
33. A monovalent attenuated serotype 2 bluetongue virus vaccine confers homologous protection in sheep.
Hunter P; Modumo J
Onderstepoort J Vet Res; 2001 Dec; 68(4):331-3. PubMed ID: 12026066
[TBL] [Abstract][Full Text] [Related]
34. DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1.
Li J; Yang T; Xu Q; Sun E; Feng Y; Lv S; Zhang Q; Wang H; Wu D
Appl Microbiol Biotechnol; 2015 Oct; 99(20):8643-52. PubMed ID: 26048472
[TBL] [Abstract][Full Text] [Related]
35. Neutralising antibody responses in cattle and sheep following booster vaccination with two commercial inactivated bluetongue virus serotype 8 vaccines.
Bartram DJ; Heasman L; Batten CA; Oura CA; Plana-Durán J; Yuen HM; Wylie AD
Vet J; 2011 May; 188(2):193-6. PubMed ID: 20466568
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and cost-benefit study to encourage herd owners in a cost sharing vaccination programme against bluetongue serotype-8 in Belgium.
Cargnel M; Van der Stede Y; Haegeman A; De Leeuw I; De Clercq K; Méroc E; Welby S
Transbound Emerg Dis; 2019 Jan; 66(1):400-411. PubMed ID: 30281942
[TBL] [Abstract][Full Text] [Related]
37. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep.
Hamers C; Rehbein S; Hudelet P; Blanchet M; Lapostolle B; Cariou C; Duboeuf M; Goutebroze S
Vaccine; 2009 May; 27(21):2789-93. PubMed ID: 19366576
[TBL] [Abstract][Full Text] [Related]
38. Protective Efficacy in Sheep of Adenovirus-Vectored Vaccines against Bluetongue Virus Is Associated with Specific T Cell Responses.
Martín V; Pascual E; Avia M; Peña L; Valcárcel F; Sevilla N
PLoS One; 2015; 10(11):e0143273. PubMed ID: 26619062
[TBL] [Abstract][Full Text] [Related]
39. Prospects of Next-Generation Vaccines for Bluetongue.
van Rijn PA
Front Vet Sci; 2019; 6():407. PubMed ID: 31824966
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of vaccination for bluetongue virus serotype 8 performed shortly before challenge and implications for animal trade.
Spedicato M; Lorusso A; Salini R; Gennaro AD; Leone A; Teodori L; Casaccia C; Portanti O; Calistri P; Giovannini A; Savini G
Prev Vet Med; 2017 Jan; 136():49-55. PubMed ID: 28010907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
